Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics
- The Atlas will expand known evolutionary genetic diversity by 100x, collecting novel genomic data from over 100 million new species across thousands of sites globally.
- By partnering with Anthropic, Ultima Genomics, and PacBio, and powered by NVIDIA AI infrastructure, Basecamp Research aims to compress over two decades of biological data gathering and analysis into less than two years.
- Training the EDEN models revealed new scaling laws: as biological datasets grow larger and richer, AI capabilities jump - opening the door to systems that can design new medicines across diseases and treatment types.
This is possible thanks to Basecamp Research's growing network of global biodiversity partners. Its ultimate goal is to provide the vast, diverse training data required for AI systems to learn from evolution to design new medicines on demand.
"Today's biological AI models are trained on a narrow slice of life on Earth," said
The initiative, which is on the scale of the Human Genome Project, was unveiled during the Health Track at SXSW and the NVIDIA GTC conference in
With huge increases in model size and computing power, diverse data is a critical enabler for progress in AI drug development and real-world benchmarks. All current sequence-based foundation models rely on variants of the same public repositories, with 80% of these trained on a public database containing fewer than 250 million sequences.
Basecamp Research's EDEN foundation models, released in January, bypass the industry's evolutionary "data wall" by training entirely on BaseData™, a proprietary genomic database that is currently more than 10 times larger than all public resources combined. By learning from an unprecedented 10 billion new-to-science genes across 1 million newly discovered species, EDEN unlocked critical new scaling laws for AI in biology.
This massive expansion in dataset diversity moved EDEN beyond simple prediction, making it the first model capable of designing diverse therapeutics directly from a disease prompt. In wet-lab validation, EDEN demonstrated zero-shot activity in primary human T-cells without any human or clinical data needed. The model has successfully generated hits across multiple frontier modalities, notably pioneering AI-Programmable Gene Insertion (aiPGI) to insert healthy genes and designing targeted antimicrobial peptides with a 97% hit rate against priority pathogens.
The Trillion
"Bigger models alone aren't enough," added
Over the past six years, Basecamp Research has built a network of scientific collaborators across 31 countries, establishing a scalable evolutionary genomics pipeline purpose-built for AI training. By pioneering a combination of new regulatory and economic frameworks and fully off-grid DNA sequencing technologies, the company collects high-quality genomic data from ecosystems beyond the reach of traditional laboratories.
These partnerships are grounded in knowledge exchange, local capacity building, and equitable Access and Benefit-Sharing agreements aligned with emerging Digital Sequence Information regulations. This framework enables responsible, large-scale, high-quality genomic data collection while investing in scientific infrastructure and training within partner regions.
As part of the Atlas launch, Basecamp is announcing new partnerships in
The Trillion
Ultima is a developer of ultra-high throughput next- generation sequencing (NGS) systems. Ultima's latest sequencing system, the UG200 Series, advances the company's unique wafer-based sequencing architecture to enable high-throughput, whole-genome and multi-omics sequencing at an industrial scale at a low price point to enable initiatives like the Trillion Atlas.
"Biology has been fundamentally data-starved when compared to other fields like language or computer vision as researchers have lacked the tools required to generate data at scale" said Gilad Almogy, Founder and CEO of Ultima Genomics. "We strongly believe that AI will have an immense impact on our understanding of biology and human health, and the UG200 Series was designed from the ground up to enable the massive datasets required for BioAI to deliver on this promise. We are excited our technology can enable Basecamp in their vision and advance innovative initiatives like the Trillion
"PacBio HiFi sequencing delivers highly accurate long reads that preserve full genomic context and enables subspecies and even strain-level resolution in complex samples." said
The Trillion
Through parallelized data processing, automated annotation, and large-scale model training, the partners expect to compress a task that previously would have required more than 20 years of processing time to less than two years. This compression of sequencing, assembly, annotation and model training is intended to expand the performance and scope of biological foundation models across therapeutic development.
Anthropic joins as part of its broader effort to add new capabilities for life sciences: connecting Claude to more scientific platforms. Working with the Claude for Life Sciences team, the aim is to harness the Trillion
By combining Claude's advanced reasoning capabilities, EDEN's therapeutic design capabilities, and NVIDIA's CUDA-X Libraries to process unstructured data, the initiative aims to create an integrated workflow for interpreting complex clinical data and translating it directly into therapeutic design.
The Trillion
View original content:https://www.prnewswire.com/news-releases/basecamp-research-launches-trillion-gene-atlas-to-scale-ai-designed-therapeutics-302716624.html
SOURCE Basecamp Research
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- InventHelp Inventor Develops New Can Cleaner (MBQ-948)
- Alpha School Expands to Santa Monica With New K-8 Campus Opening Fall 2026
- CPSC Posts New Product Recalls and Product Safety Warnings to its Web Site
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share